2024-09-23 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**Company Overview:** Vertex Pharmaceuticals Inc. is a leading biotechnology company focused on the development and commercialization of therapies for serious diseases.

**1. Performance and Outperformance:**

* **Cumulative Return:** VRTX has achieved a cumulative return of 170.91%, outperforming the S&P 500 (VOO) with a cumulative return of 132.53%.
* **Outperformance:**  VRTX has outperformed VOO by 38.38%, which represents a relative outperformance position of 73.35% compared to the historical range of outperformance.

**2. Recent Price Movement:**

* **Closing Price:** $464.92
* **5-day Moving Average:** $477.90
* **20-day Moving Average:** $479.21
* **60-day Moving Average:** $481.84

The recent price action suggests a slight downward trend, with the closing price below the 5-day, 20-day, and 60-day moving averages. 

**3. Technical Indicators:**

* **RSI:** 32.83 - This indicates that the stock is currently in oversold territory.
* **PPO:** -0.15 - This suggests potential downward momentum.
* **Delta_Previous_Relative_Divergence:** -8.95 - This indicates a recent short-term decline in relative outperformance.
* **Expected Return:** 21.45% - This represents the maximum expected return over 5 years based on current investment amount. 

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue | 
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ | 
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

The most recent earnings report for the quarter ending August 2024 showed an EPS of -13.92, significantly lower than analysts' expectations. While revenue remained consistent with previous quarters, the negative EPS suggests potential challenges in the company's profitability. Further analysis of the earnings call transcript and management commentary is required for a more comprehensive understanding of the recent earnings performance and future outlook. 

**5. Comprehensive Analysis:**

VRTX has exhibited strong long-term outperformance compared to the S&P 500. However, recent price action suggests a potential short-term downtrend. The RSI and PPO indicators also indicate oversold conditions and potential downward momentum. The recent earnings report for the quarter ending August 2024 showed a significant decline in EPS, which may be a cause for concern. 

**6. Conclusion:**

Overall, while VRTX boasts a strong history of outperformance, current technical indicators and recent earnings suggest potential short-term headwinds. Further analysis of the company's future outlook and upcoming earnings reports is essential for a comprehensive investment decision. 
